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Abstract
 
Apoptotic and mitogenic stimuli activate c-Jun NH
 
2
 
-terminal kinases (JNKs) in T cells. Al-
though T cells express both JNK1 and JNK2 isozymes, the absence of JNK2 alone can result in
resistance to anti-CD3–induced thymocyte apoptosis and defective mature T cell proliferation.
Similar defects in thymocyte apoptosis and mature T cell proliferation, the latter due to re-
duced interleukin 2 production, are also caused by JNK1 deficiency. Importantly, T cell func-
tion was compromised in 
 
Jnk1
 
1
 
/
 
2
 
Jnk2
 
1
 
/
 
2
 
 double heterozygous mice, indicating that JNK1 and
JNK2 play similar roles in regulating T cell function. The reduced JNK dose results in defec-
tive c-Jun NH
 
2
 
-terminal phosphorylation in thymocytes but not in peripheral T cells, in which
nuclear factors of activated T cells (NK-ATs)–DNA binding activity is affected. Thus, JNK1
and JNK2 control similar functions during T cell maturation through differential targeting of
distinct substrates.
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Introduction
 
The c-Jun NH
 
2
 
-terminal kinase (JNK)
 
1
 
 signaling pathway
is activated by a plethora of stimuli resulting in the potenti-
ation of the activity of transcription factors such as c-Jun
and activating transcription factor 2 (ATF2) in various cell
types, which in turn regulates diverse biological processes.
JNK signaling has also been implicated in multiple T cell
functions. In general, T cell activation involves several
steps, including the induction of immediate early genes,
followed by the induction of IL-2, a growth factor whose
secretion leads to autocrine and paracrine T cell prolifera-
tion (1). The JNKs are synergistically activated by costimu-
lation of the TCR with antibodies to its CD3 component
and the CD28 auxiliary receptor or by combined treatment
 
with PMA and Ca
 
2
 
1
 
 ionophore (2–4). This synergistic JNK
activation response is unique to T and B cells (2, 3, 5) and
was shown to correlate with IL-2 gene induction in the T
cell tumor line Jurkat (2). Anergic T cells were shown to
exhibit a defective JNK activation response (6, 7).
 
The importance of JNK activity for T cell activation and
IL-2 production is also suggested by the role of AP-1
dimers, composed of Jun and Fos subunits. Besides the
binding to its own recognition sites, AP-1 can cooperate
 
with the Ca
 
2
 
1
 
-responsive, cyclosporin A–sensitive nuclear
factor of activated T cells (NF-ATc), stabilizing the bind-
ing to the composite nuclear factors of activated T cells
(NF-ATs) recognition element in the IL-2 promoter (8).
In nonstimulated T cells, basal levels of AP-1 proteins are
 
low but T cell activation results in rapid induction of 
 
jun
 
and 
 
fos
 
 genes (2, 9). This process is partially dependent on
JNK activation (2) and consistent with the defect in JNK
activation, anergic T cells exhibit a deficient AP-1 tran-
scriptional response (10). In addition to stimulating preex-
isting transcription factors, such as c-Jun, ATF2, and Elk-1
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Abbreviations used in this paper:
 
 dn, dominant negative;
 
 
 
DP, double
positive; ES, embryonic stem;
 
 
 
GST, glutathione 
 
S
 
-transferase;
 
 
 
JNK,
c-Jun NH
 
2
 
-terminal kinase; NF-ATc, cyclosporin A–sensitive NF-AT;
NF-AT, nuclear factors of activated T cell. 
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involved in 
 
c-jun
 
 and 
 
c-fos
 
 induction, the JNKs phosphory-
late newly synthesized Jun proteins and enhance their abil-
ity to activate transcription (11, 12). Full induction of IL-2
expression also requires the stabilization of its mRNA,
which in nonstimulated T cells has a very short half-life
(13). Recent studies indicate that the JNKs are also in-
volved in activation-induced IL-2 mRNA stabilization
(14). Analysis of this process in Jurkat cells indicates that
this function is unique to the JNKs and that neither extra-
cellular signal–regulated kinases
 
 
 
nor the p38s have such a
role.
Although the loss of c-Jun, a classical JNK target, results
in embryonic lethality impeding further immunological
analysis (15), 
 
c-jun
 
2
 
/
 
2
 
 lymphoid cells were generated by the
recombination activating gene 2 (RAG2) complementation
which showed incomplete restoration of thymocytes (16).
Nonetheless, the importance of JNK-mediated phosphory-
lation of c-Jun in T cell functions has not been critically
addressed. Besides c-Jun, the role of NF-ATc components
(NF-ATc1–c4) in T cell functions has been extensively ad-
dressed. NF-ATc1
 
2
 
/
 
2
 
 T cells show a decrease in activa-
tion-induced proliferation (17), whereas the absence of
NF-ATc2 and NF-ATc3 results in the hyperactivation of
peripheral T cells (18, 19). Moreover, the overexpression
of dominant negative (dn) NF-AT proteins in T cells re-
sults in markedly reduced IL-2 production (20), indicating
that NF-ATc1 is a positive mediator of T cell activation.
On the other hand, NF-ATc3 was shown to be a target of
JNK that negatively regulates NF-ATc3 translocation to
the nucleus in Jurkat cells (21).
JNK1 and JNK2 are ubiquitously expressed in adult
mice, whereas JNK3 expression is mostly restricted to the
brain (22). Although the predominant isoform of JNK2 ex-
hibits higher affinity to c-Jun than the predominant JNK1
isoform in vitro, other isoforms of JNK1 exhibit high affin-
ity to c-Jun while certain JNK2 isoforms generated by al-
ternate splicing display low affinity towards c-Jun (11, 23,
24). To understand the physiological functions, knockout
mice lacking individual 
 
Jnk
 
 genes and transgenic mice ex-
pressing a dn 
 
Jnk1
 
 gene have been generated. The absence
of JNK2 and JNK1 resulted in impaired T cell activation,
although T and B lymphocyte development was unaltered
(25–27). JNK2 was also found to be required for IFN-
 
g
 
production by Th1 cells (26). Moreover, activation-
induced thymocyte death was affected, as 
 
Jnk2
 
2
 
/
 
2
 
 double
positive (DP) thymocytes were resistant to apoptosis in-
duced by the pan-T cell–activating anti-CD3 antibody
(25). These data suggested a role for JNK2 in T cell activa-
tion that is not fully compensated for by other JNK iso-
forms. JNK1 was shown to negatively regulate the produc-
tion of Th2 cytokines, and this altered response of Th cells
was attributed to increased nuclear accumulation of NF-
ATs (27). In addition, 
 
Jnk1
 
2
 
/
 
2
 
 T cells were found to be
hyperproliferative, whereas the expression of dn 
 
Jnk1
 
 was
shown to result in reduced T cell proliferation (27, 28).
Surprisingly, no increase in IL-2 production was found as-
sociated with increased proliferation of 
 
Jnk1
 
2
 
/
 
2
 
 T cells. We
also generated mice lacking JNK1 to define the role of
 
JNK1 in both T cell proliferation and apoptosis. No defects
in T and B cell development were observed in mice lack-
ing JNK1; however, these mice exhibited impaired activa-
tion of mature T cells, leading to reduced IL-2 production
and proliferation which was rescued by exogenous IL-2. As
shown for JNK2, immature thymocytes lacking JNK1 are
resistant to anti-CD3–induced apoptosis, suggesting that
JNK1 and JNK2 have similar functions in T cells. Impor-
tantly, 
 
Jnk1
 
1
 
/
 
2
 
Jnk2
 
1
 
/
 
2
 
 double heterozygous mice exhibit
essentially the same defects in T cell function as 
 
Jnk1
 
2
 
/
 
2
 
 or
 
Jnk2
 
2
 
/
 
2
 
 single homozygous mice. In addition, we find that
in mature T cells, JNK activity is required for the induction
of NF-AT–DNA binding activity instead of being involved
in c-Jun NH
 
2
 
-terminal phosphorylation.
 
Materials and Methods
 
Generation of Jnk1
 
2
 
/
 
2
 
 Mice by Gene Targeting.
 
A targeting
construct for the inactivation of the 
 
Jnk1 
 
locus
 
 
 
was made by sub-
cloning a HindIII-XmnI fragment containing sequences encod-
ing the first 73 amino acids of JNK1 in-frame with the 
 
lacZ
 
 gene
in the pGNA vector. The diphtheria toxin A gene was used as a
negative selection marker together with the MCI promoter in
pGNA containing 
 
Jnk1
 
 sequences (25). E14.1 embryonic stem
(ES) cells were electroporated with Pme1-linearized 
 
Jnk1
 
 target-
ing construct, selected in the presence of 300 
 
m
 
g/ml G418, and
screened by Southern blotting for homologous recombination
(25). DNA from ES cells was digested with HindIII and probed
with a 1.8-kb Xba1 fragment (see Fig. 1 a). The probe detects a
7.5-kb fragment from the wild-type allele and a 9.5-kb fragment
from the targeted allele. Targeted ES cell clones were injected
into blastocysts of C57BL/6J mice, and the chimeras were trans-
mitted efficiently to the germline. Heterozygous mice were inter-
bred to obtain 
 
Jnk1
 
2
 
/
 
2
 
 mice, which were genotyped by PCR
using the following primers: 5
 
9
 
-CACATACACTCAGTG-
GATCT-3
 
9
 
 and 5
 
9
 
-CACTATTGCCTTAAGACTCC-3
 
9
 
, which
detect the wild-type allele, and 5
 
9
 
-CACATACACTCAGTG-
GATCT-3
 
9
 
 and 5
 
9
 
-CTGATCTTCCAGATAACTGC-3
 
9
 
, which
detect the mutant allele. For all experiments, sex-matched litter-
mates of 
 
Jnk1
 
1
 
/
 
2
 
 intercrosses were used, and mice were handled
according to the Austrian laws governing the use of animals for
research.
 
Western Blot Analysis and JNK Assay.
 
Western blot analysis
was performed using 100 
 
m
 
g of whole cell extracts of primary
embryonic fibroblasts, splenic, lymph node, and thymic cells ac-
cording to standard procedures. Cell extracts were prepared as de-
scribed (23), separated on a 10% SDS-PAGE, transferred onto
Immobilon-P membrane (Millipore), and probed with anti-JNK1
(333.8), anti-JNK (666.8; BD PharMingen), anti–c-Jun (Trans-
duction Laboratories), and anti–phospho-c-Jun (S63; a gift from
Drs. D. Lallemand and M. Yaniv, Pasteur Institute, Paris, France)
antibodies. Kinase assays were performed using 60 
 
m
 
g of whole
cell extracts and glutathione 
 
S
 
-transferase (GST)–c-Jun (1-79) as a
substrate and quantified on a Molecular Dynamics PhosphorIm-
ager. Relative JNK activity is represented by pixel values obtained
by quantification of the intensity of the signal. Parallel samples
were analyzed for protein expression by immunoblotting with the
above antibodies as well as an antibody to actin (Sigma-Aldrich).
 
Flow Cytometric Analysis.
 
Single cell suspensions of thymi and
spleens were prepared, and 10
 
6
 
 cells were stained in PBS contain-
ing 1% FCS for 1 h at 4
 
8
 
C. Monoclonal antibodies used for stain- 
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ing were FITC-conjugated anti-CD8, anti-IgM, anti-CD43,
anti–IL-2R
 
a
 
, and PE-conjugated anti-B220, anti-CD4, and anti-
CD3 (all from BD PharMingen). Analyses were performed on a
FACScan™ flow cytometer (Becton Dickinson) using CELL
Quest™ software.
 
Proliferation Assays and ELISA.
 
Total spleen and lymph node
cells as well as T cells purified from spleens were used for the pro-
liferation assays. Splenic T cells were purified by FACS
 
®
 
 sorting
using anti-CD4 and anti-CD8 antibodies. Cells were plated in
96-well plates, precoated with anti-CD3
 
e
 
 antibody for 2 h at
37
 
8
 
C, in the presence or absence of anti-CD28 antibody (BD
PharMingen). Cells were also cultured in the absence or presence
of 5 
 
m
 
g/ml concanavalin A. After 60 h, cultures were pulsed for
10–12 h with 1 
 
m
 
Ci of [
 
3
 
H]thymidine/well, and cells were subse-
quently harvested and analyzed by standard procedures. T lym-
phocytes stimulated with anti-CD3
 
e
 
 antibody for 24 h were har-
vested, and the supernatants were used to measure IL-2 levels by
ELISA (R&D Systems). 50 U/ml IL-2 was added to cells for pro-
liferation assays when indicated. B cell proliferation was analyzed
by the stimulation of B220
 
1
 
 spleen cells with 50 U/ml IL-4, 1
 
m
 
g/ml soluble anti-CD40, or 10 
 
m
 
g/ml LPS. The magnitude of
stimulated [
 
3
 
H]thymidine incorporation was used as an indicator
of cell proliferation. The results are representative of at least three
independent experiments, each using three pairs of mice. All ex-
periments were performed in triplicates.
 
In Vivo Thymocyte Death Assay.
 
12-wk-old wild-type (
 
Jnk1
 
1/1
 
)
and 
 
Jnk1
 
2
 
/
 
2
 
 
 
mice were injected with either PBS or various
doses of purified anti-CD3
 
e
 
 antibody (BD PharMingen) intra-
peritoneally. After 48 h, mice were killed and thymi were re-
moved. Single cell suspensions were prepared and subjected to
flow cytometric analysis after staining with the appropriate anti-
bodies.
 
In Vitro Apoptosis Assays.
 
Freshly isolated thymocytes were
cultured in DMEM containing 10% FCS, glutamine, pyruvate,
penicillin, and streptomycin and were plated at 5 
 
3
 
 10
 
5
 
 cells/ml
in each well of a 24-well dish. For anti-CD3
 
e
 
–induced cell
death, wells were precoated with various concentrations of the
antibody for 1 h at 37
 
8
 
C, washed three times in PBS, and thy-
mocytes were subsequently cultured for the indicated periods in
the presence of 1 
 
m
 
g/ml anti-CD28. Apoptosis was also induced
by the addition of various concentrations of anti-Fas antibody
(Jo-2 clone; BD PharMingen), dexamethasone (Fluka), or by
UVC irradiation (40 or 80 J/m
 
2
 
) using a Stratagene cross-linker.
After incubation for the indicated periods at 37
 
8C in a 5% CO2
atmosphere, the cells were harvested and stained with FITC-con-
jugated annexin V (BD PharMingen) and propidium iodide and
analyzed with a FACScan™ cytometer as described above. Thy-
mocytes cultured in medium alone served as controls to measure
spontaneous rate of cell death. Thymocyte viability is expressed as
the percentage of viable thymocytes treated with apoptotic stim-
uli over viability of untreated thymocytes. The results are repre-
sentative of four independent experiments, each using three pairs
of mice. All experiments were performed in duplicates.
Nuclear Extracts and Electrophoretic Mobility Shift Assay. Nu-
clear extracts were prepared from 107 spleen and lymph node
cells as described (12). Binding reactions were conducted using
the indicated amount of nuclear extracts and 3 3 104 cpm of 32P
end-labeled double stranded oligonucleotides. The double
stranded oligonucleotides used in the mobility shift assay were
from the human osteocalcin AP-1 site (59-GGGTGACTCAC-
CGGGTGAA-39) and from the distal NF-AT binding site of
the human IL-2 promoter (59-GATCGGAGGAAAAACTGTT-
TCATACAGAAGGCGT-39) and human IL-4 promoter (59-
GTAATAAAATTTTCCAATGTAAA-39). For supershift ex-
periments, 2 mg of anti–c-Jun (SC-44; Santa Cruz Biotechnol-
ogy, Inc.) and anti–NF-ATc1 and NF-ATc2 (a gift of Dr. G.
Crabtree, Stanford Medical School, Stanford, CA) were added to
the reactions.
Results
Generation of JNK1-deficient Mice. The  Jnk1  gene was
inactivated by homologous recombination in ES cells using
a targeting construct that lacks parts of the kinase domain
(Fig. 1 a). Heterozygous mice were intercrossed to produce
homozygous animals (Fig. 1 b), which were viable and ex-
hibited no anomalies at birth. Western blot analysis con-
firmed the absence of both JNK1 long and short isoforms
in primary embryonic fibroblasts (Fig. 1 c). Both JNK2 iso-
forms were present at similar levels in wild-type, Jnk11/2,
and Jnk12/2 cells (Fig. 1 c). These results indicate that the
targeted mutation of the Jnk1 gene results in the complete
absence of a functional gene product.
Figure 1. Targeted mutation of the murine Jnk1 gene in ES cells. (a)
The structure of Jnk1 genomic DNA encoding a portion of the JNK1
protein kinase domain (top). The targeting vector (middle) replaced parts
of exon 2 with a b-galactosidase gene fused in-frame with exon 2 and a
Neor cassette driven by the Rous sarcoma virus promoter. The structure
of the targeted allele after homologous recombination is depicted (bot-
tom). DT-A, diphtheria toxin A gene used for negative selection. (b)
Genotyping of offspring of mice heterozygous for the targeted Jnk1 muta-
tion. Tail DNA was digested with HindIII and analyzed by Southern blot
analysis using the probe indicated in panel a. (c) Western blot analysis of
JNK protein expression in primary embryonic fibroblasts. Whole cell ex-
tracts (100 mg protein) from wild-type (1/1), heterozygous (1/2), and
homozygous mutant (2/2) embryonic fibroblasts were separated by
SDS-PAGE, transferred to a membrane, and probed with anti-JNK anti-
bodies. The positions of the long (L) and short (S) isoforms of the JNK
proteins are indicated.320 Role of JNK1 in T Cell Apoptosis and Proliferation
Lymphocyte Development Is Not Altered in the Absence of
JNK1. Although JNK signaling was suggested to be in-
volved in the development of both T and B lymphocytes
(29, 30), neither was altered in the absence of JNK1 (data
not shown). Thymi of Jnk12/2 mice had normal num-
bers of CD41CD81, CD41CD82, CD42CD81, and
CD42CD82 cells (data not shown). Moreover, Jnk12/2
splenic cells were comparable to wild-type cells as deter-
mined by staining with antibodies to CD4, CD8, CD3,
heat stable antigen (HSA), TCR-a/b, TCR-g/d, Thy1.2,
CD25, CD44, and B220 (data not shown). Cell numbers
were also comparable between wild-type and mutant
spleens, thymi, and lymph nodes.
Lack of JNK1 Results in Increased Resistance to Anti-CD3–
induced Thymocyte Apoptosis In Vivo. We next deter-
mined if T cell function is altered in the absence of JNK1.
Both Jnk12/2 and wild-type mice were injected intraperi-
toneally with various doses of the anti-CD3e antibody,
which is a potent activator of T cells, and analyzed for de-
pletion of DP CD41CD81 thymocytes. Wild-type mice
injected with 10 mg of anti-CD3 contained z55% DP cells
compared with PBS-treated mice which had z89% DP
cells, 48 h after injection (Table I). By contrast, Jnk12/2
mice contained almost similar levels of DP cells (81%)
compared with PBS-treated mice (87%; Table I). Injection
of higher doses of the antibody resulted in increased thy-
mocyte cell death both in wild-type and Jnk12/2 mice.
However, Jnk12/2 mice were more tolerant to intermedi-
ate doses of the antibody, with z56% DP remaining after
injection of 30 mg antibody, compared with only 38% sur-
vival in wild-type mice (Table I). At the highest dose of 60
mg antibody almost all the DP cells were dead (3% left) in
wild-type mice, whereas z10% of the DP cells remained in
Jnk12/2 mice. Thus, absence of JNK1 confers partial resis-
tance to anti-CD3 antibody–induced thymocyte apoptosis
in vivo, as was found with Jnk22/2 mice (25).
Thymocyte Survival in Response to Various Apoptotic Stimuli
In Vitro. We investigated if the observed resistance of
Jnk12/2 thymocytes to anti-CD3 antibody–induced cell
death in vivo is a cell-autonomous defect. Thymocytes
from wild-type and Jnk12/2 mice were incubated in vitro
with anti-CD3 antibody, in the presence of anti-CD28 an-
tibody that provides the auxiliary signal, and cell viability
was determined. Wild-type thymocytes underwent cell
death in a dose-dependent manner, when assayed at 24 h
(Fig. 2 a). By comparison, Jnk12/2 thymocytes were par-
tially resistant to anti-CD3–induced cell death (Fig. 2 a). At
the highest concentration of the antibody (100 mg/ml),
70% of wild-type thymocytes were viable compared with
85% of Jnk12/2 thymocytes. A similar pattern was observed
at lower doses of the anti-CD3 antibody: 77% of wild-type
cells were alive compared with 92% live Jnk12/2 cells at 10
mg/ml of anti-CD3; and 88% viability of wild-type cells
compared with 98% viability of Jnk12/2 cells at 1 mg/ml of
antibody (Fig. 2 a). Jnk12/2 thymocytes were still more re-
sistant than their wild-type counterparts even after 48 h of
incubation with anti-CD3 antibody. At this time point,
z40% of the wild-type thymocytes incubated with 100
mg/ml of antibody were alive, compared with 62% of the
Jnk12/2 thymocytes (Fig. 2 b). This trend was also ob-
served at a lower dose of antibody: 59% of wild-type thy-
mocytes were viable compared with 76% viable Jnk12/2
thymocytes (Fig. 2 b). These results were consistently and
reproducibly obtained in many experiments. Nonetheless,
the resistance to anti-CD3–induced death observed in vitro
is not as extensive as the resistance observed in vivo, sug-
gesting that the in vivo effect could be a result of both di-
rect and indirect effects of the anti-CD3 treatment.
As JNK signaling was suggested to be generally involved
in responses to apoptotic stimuli, we determined the re-
sponse of wild-type and Jnk12/2 thymocytes to other ap-
optosis-inducing agents. There was no appreciable difference
in viability between wild-type and Jnk12/2 thymocytes
over various doses of dexamethasone, anti-Fas antibody,
and UVC radiation regardless of the time point after treat-
ment at which the cells were analyzed (Fig. 2, c–h). There-
fore, like JNK2, JNK1 is involved in transducing cell death
signals in response to the anti-CD3 antibody but is not re-
quired in response to other proapoptotic stimuli.
Activation of Peripheral T Cells, but Not B Cells, Is Impaired
in the Absence of JNK1. It has been reported that cytokine
production by activated peripheral T cells can induce the
expression of cell death mediators or permissive factors that
will result in DP thymocyte death in vivo (31). As the
magnitude of anti-CD3–induced cell death in vitro was
lower than what was observed in vivo, we examined if pe-
ripheral T cell activation was affected by the absence of
JNK1. Total spleen cells, lymph node cells, and purified
splenic T cells were stimulated with various doses of plate-
bound anti-CD3 and soluble anti-CD28 antibodies or con-
canavalin A, and the proliferation rates were determined.
Both wild-type and Jnk12/2 total spleen cells proliferated
vigorously and no significant differences were observed
over a broad range of anti–CD3 antibody concentrations
Table I. JNK1-deficient Thymocytes Are Resistant to Cell Death 
Induced by Anti-CD3 Antibody In Vivo
Percent surviving CD41CD81 thymocytes
Treatment JNK11/1 JNK12/2
PBS 89 6 5 87 6 6
Anti-CD3 10 mg 55 6 7 81 6 7
Anti-CD3 30 mg 38 6 8 56 6 5
Anti-CD3 60 mg3   6 3 10 6 4
Lack of JNK1 results in the increased resistance of immature thymocytes
to anti-CD3 antibody–induced cell death. 12-wk-old wild-type and
Jnk12/2 mice were injected with PBS or indicated amounts of anti-CD3
antibody and thymi were removed for analysis after 48 h. Single cell
suspensions of thymocytes were stained with anti-CD4 and anti-CD8
fluorescent antibody conjugates and analyzed by flow cytometry. The
results are representative of at least five mice per group.321 Sabapathy et al.
(Fig. 3 a). However, lymph node cells from Jnk12/2 mice
exhibited a proliferation defect that was apparent only at
lower doses of the activating stimuli (Fig. 3 b). Purified
splenic T cells from Jnk12/2 mice also exhibited a prolifer-
ation defect which was present at all concentrations of
stimuli (Fig. 3 c).
The levels of IL-2 produced 24 h after T cell activation
from purified Jnk12/2 splenic T cells were significantly re-
duced at lower doses of the activating anti-CD3 and anti-
CD28 antibodies (Fig. 3 d). However, the levels of IL-2
production by both wild-type and Jnk12/2 T cells were
comparable at the highest dose of the activating stimuli
(Fig. 3 d). These data correlate with the proliferation data,
suggesting that the proliferation defect is due to insufficient
production of IL-2. Indeed, whereas the IL-2 receptor a
chain was expressed at similar levels in both wild-type and
Jnk12/2 cells (data not shown), the addition of exogenous
IL-2 completely suppressed the proliferation defect of
Jnk12/2 T cells (Fig. 3 e).
As JNK signaling was suggested to be involved in B cell
activation (32), we determined if JNK1-deficient B cells
were impaired in their response to activating stimuli. Prolif-
eration rates of splenic B cells stimulated with various doses
of LPS or anti-CD40 and IL-4 were comparable between
wild-type and Jnk12/2 mice (Fig. 3 f, and data not shown).
Moreover, Jnk12/2 B cells normally upregulated CD23 ex-
pression upon CD40 stimulation (data not shown). Thus,
JNK1 deficiency does not appear to affect B cell activation.
Figure 2. In vitro susceptibility of Jnk12/2 thy-
mocytes to death caused by direct incubation with
anti-CD3 antibody and other apoptotic stimuli. (a–b)
Thymocytes from wild-type (e) and Jnk12/2 (j)
mice were cultured on 24-well plates coated with
anti-CD3e antibody for (a) 24 h or (b) the indi-
cated time periods in the presence of the indicated
concentrations of soluble anti-CD28 antibody, and
cell viability was determined. There was no differ-
ence in spontaneous (i.e., basal) cell death rates be-
tween wild-type and Jnk12/2 thymocytes. (c–h)
Cell death was determined after treatment of thy-
mocytes with: (c) various concentrations of dexa-
methasone; (e) various doses of UVC irradiation;
(g) incubation with various concentrations of anti-
Fas antibody for 24 h; (d) 1029 M dexamethasone;
(f) 80 J/m2 of UVC irradiation; or (h) 0.05 mg/ml
of anti-Fas antibody for the indicated time periods.
These results are representative of four independent
experiments, each using three pairs of mice. All as-
says were conducted in triplicates. Standard devia-
tions are indicated by vertical lines.322 Role of JNK1 in T Cell Apoptosis and Proliferation
Defective Apoptosis and Proliferation in Double Heterozygous
Jnk11/2 Jnk21/2 Cells. The apoptosis and proliferation
defects displayed by Jnk12/2 thymocytes and peripheral T
cells are similar to those found in T cells lacking JNK2 (25).
This raised the possibility that JNK1 and JNK2 have similar
and overlapping roles in T cell signal transduction. The
phenotypes exhibited by either Jnk12/2 or Jnk22/2 mice
could therefore be due to a reduction in the total amount
of JNK activity. Unfortunately, Jnk12/2Jnk22/2 double
mutant fetuses die at E11.5 (33, 34), and the analysis of
double mutant T cells could only be performed in chimae-
ras with mutant ES cells (35). To test whether gene dosage
could account for the observed T cell defects, T cell func-
tion was analyzed in Jnk11/2Jnk21/2 double heterozygotes.
Thymocytes from wild-type, Jnk11/2, Jnk21/2, Jnk12/2,
Jnk22/2,  Jnk11/2Jnk21/2,  Jnk12/2Jnk21/2, and Jnk11/2
Jnk22/2 mice were isolated and treated with anti-CD3
and anti-CD28 antibodies to determine the apoptotic re-
sponse. Jnk11/2Jnk21/2 double heterozygote thymocytes
were as resistant as Jnk12/2 or Jnk22/2 single knockout
thymocytes (Fig. 4), suggesting that the loss of a single al-
lele of each Jnk gene is functionally equivalent to the loss of
both alleles of a single gene. Single heterozygotes, Jnk11/2
Jnk21/1 or Jnk11/1Jnk21/2, however, had no phenotype
(Fig. 4). Moreover, loss of three Jnk alleles, namely Jnk12/2
Jnk21/2 or Jnk11/2Jnk22/2, did not enhance the defect in
activation-induced cell death (Fig. 4).
Peripheral T cells from the above mice were also exam-
ined for the proliferative response to anti-CD3 plus anti-
CD28 stimulation. Total spleen cells activated with either
anti-CD3 antibody alone or concanavalin A exhibited a
vigorous proliferative response regardless of genotype (Fig.
5 a, and data not shown). However, lymph node T cells
from all mutant mice displayed a marked proliferative de-
fect when exposed to low doses of anti-CD3 antibody (Fig.
5 b). Both Jnk12/2 and Jnk22/2 T cells proliferated much
less efficiently than wild-type cells when stimulated with 1
mg/ml of anti-CD3 antibody (Fig. 5 b). Most importantly,
lymph node T cells from Jnk11/2Jnk21/2, as well as from
Jnk12/2Jnk21/2 or Jnk11/2Jnk22/2 mice, exhibited a simi-
lar proliferative defect to the single knockout cells (Fig. 5
b). Nevertheless, T cells from single heterozygotes, Jnk11/2
Jnk21/1 or Jnk11/1Jnk21/2, did not display any prolifera-
tion defect (Fig. 5 b).
Figure 3. Inefficient proliferation and IL-2
production by T cells lacking JNK1. (a–c)
Cells from (a) spleen, (b) lymph nodes, or
(c) purified splenic T cells, all from 4–8-wk-
old Jnk11/1 or Jnk12/2 mice, were cultured
in the presence of the indicated concentra-
tions of plate-bound anti-CD3e antibody in
the absence or presence of the indicated
amounts of anti-CD28 antibody. After 60 h,
cells were pulsed for 12 h with 1 mCi
[3H]thymidine/well and collected for mea-
surement of [3H]thymidine incorporation
into DNA. (d) IL-2 production was mea-
sured by ELISA on media collected 24 h af-
ter stimulation of purified splenic T cells as
described above. (e) Proliferation rates of
purified T cells cultured in the presence of
50 U/ml IL-2 plus anti-CD3 and/or anti-
CD28 antibodies. Proliferation rates of
splenic B cells cultured in medium alone
(untreated), or in the presence of either 50
U/ml IL-4 plus 1 mg/ml soluble anti-CD40
or 10 mg/ml LPS. The results are represen-
tative of four independent experiments,
each using three matched pairs of mice. All
assays were conducted in triplicates. Stan-
dard deviations are shown as vertical lines.323 Sabapathy et al.
c-Jun Phosphorylation in the Absence of JNK1. Activation
of the JNK pathway leads to phosphorylation of various
substrates, including c-Jun, and results in target gene induc-
tion (36). We investigated whether the defects observed in
Jnk12/2 thymocytes and mature T cells were due to defec-
tive c-Jun phosphorylation. Both wild-type and JNK1-defi-
cient thymocytes were stimulated with anti-CD3 and anti-
CD28, and cell lysates prepared at various time points after
stimulation were used to determine total JNK activity, us-
ing GST–c-Jun (1-79) as a substrate. JNK activity was ele-
vated 30 min after stimulation of wild-type thymocytes
(Fig. 6 a). This increase persisted at 75 min after stimula-
tion, but kinase activity returned to near basal levels by 240
min (Fig. 6 a). By contrast, JNK activity was only margin-
ally elevated between 30 and 75 min after stimulation in
Jnk12/2 thymocytes and the entire response appeared to be
delayed (Fig. 6 a). We also examined the NH2-terminal
phosphorylation of endogenous c-Jun by Western blot
analysis with anti–phospho-c-Jun (S63) antibodies. An in-
crease in the amount of JNK-phosphorylated c-Jun was
observed at z10 min and remained elevated for at least 240
min after stimulation in wild-type thymocytes (Fig. 6 a).
After the appearance of phosphorylated c-Jun, the total
amount of c-Jun protein also increased and peaked at 240
min after stimulation (Fig. 6 a). These results are consistent
with the known autoregulation of c-jun transcription (37).
However, in Jnk12/2 thymocytes no c-Jun NH2-terminal
phosphorylation could be detected, and the total amount of
c-Jun was also very low and not induced upon stimulation
(Fig. 6 a). These results indicate that c-Jun is an important
target for JNK1 in anti-CD3–activated thymocytes.
Total JNK activity was also elevated in wild-type pe-
ripheral T cells activated with anti-CD3 and anti-CD28
antibodies, starting at 10 min after stimulation and peaking
at z75 min after stimulation (Fig. 6 b). By contrast, no in-
crease in total JNK activity was observed in Jnk12/2 pe-
ripheral T cells (Fig. 6 b). Western blot analysis of endoge-
nous c-Jun phosphorylation and expression revealed that
although total c-Jun protein amount was modestly elevated
after the stimulation of wild-type cells, only a marginal in-
crease in c-Jun NH2-terminal phosphorylation could be
detected (Fig. 6 b). These results suggest that by contrast to
thymocytes, c-Jun might not be an important downstream
target for JNK in peripheral T cells. Analysis of Jnk12/2 pe-
ripheral T cells revealed only a slight increase in the total
c-Jun expression, less than in activated wild-type T cells,
and no significant increase in c-Jun NH2-terminal phos-
phorylation (Fig. 6 b).
NF-AT Binding Activity Is Reduced in JNK1 Mutant Pe-
ripheral T Cells. To identify potential targets for JNK1 in
peripheral T cells, we performed electrophoretic mobility
shift assay using nuclear extracts from nonactivated and ac-
Figure 4. Jnk11/2Jnk21/2 thymocytes are resis-
tant to anti-CD3 activation–induced cell death.
Thymocytes from mice of various genotypes were
cultured with anti-CD3e and anti-CD28 antibod-
ies for 24 h and their viability was determined as
described. The results are representative of three
independent experiments, each using three
matched pairs of mice. All assays were conducted
in triplicates. Standard deviations are shown as ver-
tical lines.
Figure 5. Impaired proliferation of Jnk11/2Jnk21/2 T cells. (a) Spleen
cells and (b) lymph node cells were cultured with 1 mg/ml of anti-CD3
antibody and proliferation rates were determined as described above. The
results are representative of three independent experiments, each using
three matched pairs of mice. All assays were conducted in triplicates.
Standard deviations are shown as vertical lines.324 Role of JNK1 in T Cell Apoptosis and Proliferation
tivated spleen and lymph node cells. The regulation of AP-1
binding activity was essentially identical in wild-type and
Jnk12/2 lymph node and spleen cells (Fig. 7 a, and data not
shown). AP-1 binding activity was induced z3 h after
stimulation and was still present at 16 h. The detected ac-
tivity was sequence specific based on competition analysis,
and all three Jun members were present at similar levels
(data not shown). Therefore, we examined whether the ac-
tivity of another critical T cell transcription factor, NF-AT,
was altered in the absence of JNK1, as the absence of NF-
ATc1 results in reduced T cell proliferation (17). Nuclear
extracts from wild-type lymph node T cells activated with
anti-CD3 and anti-CD28 antibodies exhibited enhanced
NF-AT–DNA binding activity to the NF-AT binding site
of the IL-2 promoter 3 h after stimulation. However, NF-
AT activity was markedly reduced in Jnk12/2 extracts (Fig.
7 b), although using five times higher amount of Jnk12/2
extracts, NF-AT–DNA binding activity could be detected
(Fig. 7 c). The presence of NF-ATc1 and NF-ATc2 in the
specific complex was confirmed by supershift analysis with
the respective antibodies (Fig. 7 c). As NF-AT–DNA bind-
ing on the IL-2 promoter is dependent on the AP-1 site,
we also examined the NF-AT–DNA binding activity using
the site from the IL-4 promoter, which is a high affinity
binding site to which NF-AT binds in an AP-1–indepen-
dent manner (8). Using increasing amount of extracts, we
found NF-AT–DNA binding activity in the wild-type ex-
tracts (Fig. 7 d). This activity was reduced in the absence of
JNK1, indicating that the defect is not due to any modifi-
cation of the AP-1 component (Fig. 7 d). However, this
defect was not absolute as we could detect NF-AT–DNA
binding activity with higher doses of extracts (Fig. 7 d).
The reduced NF-AT–DNA binding activity in Jnk12/2 T
cell extracts is not due to inefficient cytoplasmic exit or nu-
clear translocation of NF-ATc1, as we observed compara-
ble amounts of NF-ATc1 in both wild-type and Jnk12/2
nuclear extracts after stimulation (Fig. 7 e).
Discussion
Mice lacking JNK1 were generated to evaluate the spe-
cific roles of JNK isozymes in T cell function. We found
that both JNK1 and JNK2 have similar and stage-depen-
dent roles in regulating T cell function. In thymocytes,
JNK1 is necessary for efficient apoptosis induced by anti-
CD3 antibody, whereas in mature T cells, it is necessary for
efficient proliferation and IL-2 production. At both devel-
opmental stages, JNK1 uses different targets in regulating
the two different processes. c-Jun phosphorylation is re-
duced in the absence of JNK1 in thymocytes, whereas it is
not affected in mature T cells. In contrast, NF-AT–DNA
binding activity is reduced in Jnk12/2 mature T cells.
These data underscore the importance of regulation of di-
vergent targets by JNK1 in transmitting signals to the nu-
cleus, which to our knowledge is the first demonstration of
such distinct control of gene expression by a signaling cas-
cade in different developmental stages of a cell type.
As found previously with Jnk22/2 thymocytes (25), im-
mature Jnk12/2 thymocytes are resistant to anti-CD3 anti-
body–induced death, both in vitro and in vivo, yet are able
to respond efficiently to other apoptotic stimuli. Thus, like
JNK2, JNK1 is involved in the transduction of apoptotic
signals generated by the massive activation of the TCR
with the anti-CD3 antibody. This defect in activation-
induced death in Jnk12/2 mice was pronounced when the
anti-CD3 antibody was administered in vivo rather than
Figure 6. JNK activity and c-Jun status in Jnk12/2 cells. (a) Thy-
mocytes and (b) lymph node cells from wild-type and Jnk12/2 mice were
stimulated for the indicated times with 10 mg/ml anti-CD3 plus 0.1 mg/
ml anti-CD28 antibodies, and JNK activity was determined in whole cell
extracts, using solid-state kinase assay and GST–c-Jun (1-79) as a sub-
strate. The same extracts were analyzed for their content of phospho-
c-Jun (S63), total c-Jun, and actin by Western blot analysis.325 Sabapathy et al.
presented in a plate-bound form to isolated thymocytes. As
peripheral mature T cells are also activated by anti-CD3
antibody–injection resulting in the release of cytokines, in-
cluding IL-2 (31), it could be envisaged that the major
consequence of the JNK1 or JNK2 deficiencies is reduced
responsiveness of mature T cells to activating stimuli. The
activation defect could result in decreased production of
death cytokines or cytokines that sensitize immature thy-
mocytes to death signals. Indeed, peripheral Jnk12/2 and
Jnk22/2 T cells exhibit a proliferation defect at limiting
doses of activating stimuli, due to reduced IL-2 production.
This proliferation defect was fully rescued by the addition
of exogenous IL-2. Interestingly, thymocytes from mice
that are deficient in the a and b subunits of the IL-2 recep-
tor or IL-2 itself exhibit decreased sensitivity to apoptosis
induced by in vitro incubation with anti-CD3 antibody
(38–40). Thus, the resistance of Jnk12/2 or Jnk22/2 thy-
mocytes to in vivo administration of anti-CD3 antibody is
probably due to a combination of a thymocyte-autono-
mous defect and decreased production of death-promoting
cytokines in the periphery. It should be noted, however,
that JNK activity is not required for all forms of thymocyte
apoptosis, as both Jnk12/2 or Jnk22/2 thymocytes were
susceptible to apoptosis induced by anti-Fas antibody, dexa-
methasone, and UVC irradiation as wild-type cells.
These results strongly suggest that JNK1 and JNK2 have
similar functions in T cell signal transduction, possibly
through phosphorylation of a common set of substrates.
Figure 7. AP-1– and NF-AT–DNA-binding ac-
tivity in JNK1-deficient T cells. (a) AP-1–DNA
binding activity was measured using 2.5 mg nuclear
extracts from untreated or 10 mg/ml anti-CD3 and
0.1 mg/ml anti-CD28–stimulated lymph node cells
for the indicated period of time. The proteins were
incubated with an AP-1 binding site oligonucle-
otide probe, and the specific protein–DNA com-
plex is indicated. (b–d) NF-AT–DNA binding
activity from untreated (2) or anti-CD3– and anti-
CD28–stimulated (3 h; 1) lymph node cells of
wild-type and Jnk12/2 mice was examined using
oligonucleotide probes corresponding to either the
low affinity NF-AT binding site from the IL-2
promoter (b and c) or the high affinity NF-AT
binding site from the IL-4 promoter (d). 2.5 mg of
nuclear extracts was used in b. In the supershift ex-
periments, 2.5 mg of wild-type extracts and 12.5
mg of Jnk12/2 extracts were used and the specific
complex was supershifted by both anti–NF-ATc1
and anti–NF-ATc2 antibodies (c). Increasing
amounts of extracts were used in d as indicated.
The specific protein–DNA complex is indicated.
(e) Cytoplasmic and nuclear extracts from unstimu-
lated (2) and stimulated (1) wild-type and Jnk12/2
lymph node T cells were prepared as described in
b–d, and NF-ATc1 protein was detected by West-
ern blot analysis.326 Role of JNK1 in T Cell Apoptosis and Proliferation
This hypothesis was tested using double heterozygote
Jnk11/2Jnk21/2 mice, which lack half of the Jnk1 and Jnk2
gene doses. The single heterozygotes displayed no defect
whatsoever in activation-induced cell death or proliferation
of peripheral T cells. However, thymocytes and T cells de-
rived from Jnk11/2Jnk21/2 double heterozygous mice had
the same defects as either Jnk12/2 or Jnk22/2 T cells. Thus,
both JNK1 and JNK2 make important but very similar
contributions to the activation of peripheral T cells and in-
duction of thymocyte apoptosis in response to TCR activa-
tion with anti-CD3. A requirement for JNK activity in
anti-CD3–induced apoptosis and peripheral T cell activa-
tion has also been demonstrated by ectopic expression of
catalytically inactive JNK1 in thymocytes (28).
The JNKs phosphorylate various substrates, among
which c-Jun has been shown to be a critical and ubiquitous
target in many cell types (36). Nonetheless, the absence of
JNK1 or JNK2 leads to defective endogenous c-Jun phos-
phorylation upon stimulation with the anti-CD3 antibody
only in immature thymocytes and not in mature T cells.
Consistent with these findings, we found using mutant
mice homozygous for a c-jun allele, in which the serines 63
and 73 were replaced with alanines, that c-Jun phosphory-
lation is essential for thymocyte apoptosis (unpublished ob-
servations). However, c-Jun does not seem to be a critical
target for either JNK1 or JNK2 in activated mature periph-
eral T cells. Total c-Jun levels in peripheral T cells do not
increase as dramatically in response to TCR activation as in
activated thymocytes. Consistent with these findings, ma-
ture T cells from the phosphorylation-defective c-Jun mu-
tant mice do not exhibit any proliferation defect (unpub-
lished observations). These results strongly suggest that as T
cells mature, JNK activation becomes linked to the phos-
phorylation of substrates other than c-Jun. Whereas c-Jun
NH2-terminal phosphorylation is linked to activation-
induced thymocyte apoptosis, the phosphorylation of these
yet to be identified substrates is linked to T cell prolifera-
tion.
Reduced peripheral T cell proliferation in both Jnk12/2
and  Jnk22/2  mutants correlates with reduced NF-AT–
DNA binding activity. Although both AP-1 and NF-AT–
DNA binding activities were induced upon activation of
wild-type T cells, only AP-1 DNA binding activity was in-
duced to normal levels in Jnk12/2 or Jnk22/2 mutants.
Lack of NF-ATc1 has been shown to result in reduced T
cell proliferation (17). Moreover, overexpression of a dn
NF-AT in T cells markedly inhibits IL-2 production (20).
It is therefore likely that the reduction in NF-AT activity
may account for the proliferation defect of JNK-deficient
T cells. It should be noted that the proliferation defect is
not absolute, as higher levels of stimulation result in in-
creased proliferation. Consistent with this, we found that
NF-AT–DNA binding activity is not abrogated in the ab-
sence of JNK1, but only reduced. Thus, the reduction in
NF-AT–DNA binding activity correlates with the prolifer-
ation defect in the absence of JNK1. It is not yet clear how
JNK activation is linked to nduction of NF-AT activity. As
the binding of NF-AT in the IL-4 promoter does not re-
quire cooperation from AP-1 (8), it is possible that the pri-
mary target for JNK phosphorylation could be a nuclear
partner, NF-ATn, whose phosphorylation could assist NF-
AT proteins in binding DNA. Alternatively, NF-AT pro-
teins themselves could be a direct target for JNK-mediated
phosphorylation. In this regard, it was reported that NF-
ATc3 is phosphorylated by the JNKs resulting in its exclu-
sion from the nucleus (41). However, these results imply
that JNKs negatively regulate NF-AT function, whereas
our data indicate that the JNKs exert a positive effect on
NF-AT function, at least in peripheral T cells. No differ-
ences in the levels of NF-ATc1 and NF-ATc2 or their sub-
cellular distribution were detected between wild-type and
Jnk12/2 cells. Thus, defective nuclear translocation cannot
explain the defect in induction of NF-AT–DNA binding
activity. Although Dong et al. (27) recently reported that
the lack of JNK1 results in nuclear accumulation of NF-
ATc1 in Th cells, we have not been able to identify such a
defect in mature T cells. Our results clearly indicate that
JNK1 has a positive rather than a negative effect on NF-
AT and T cell activation and that JNK1 and JNK2 play
similar and overlapping roles in T cell function.
Recently, lack of JNK1 was reported to result in hyper-
proliferation of purified CD41 Th peripheral T cells with-
out an increase in IL-2 production (27), whereas the ab-
sence of JNK2 had no effect on mature T cell proliferation
but affected IFN-g production by Th1 cells (26). In neither
case was a defect in IL-2 production observed, which gen-
erally reflects the proliferative capacity of T cells. Further-
more, lack of both JNK1 and JNK2 results in hyperprolif-
eration and increased IL-2 production in CD41 Th cells
(35). However, transgenic mice expressing a catalytically
inactive, dn Jnk1 gene showed reduced mature T cell pro-
liferation (28). Most of the experiments performed with
these JNK-deficient mice employed CD41 Th1 and Th2 T
cells generated by in vitro differentiation (26, 27). In con-
trast, we examined peripheral T cells isolated from spleen
and lymph nodes which, with the exception of mitogenic
stimulation, were not subjected to any long-term in vitro
manipulation. Our results clearly support the observations
with the dn Jnk1 transgenic mice and indicate that JNK1
positively regulates proliferation. Moreover, thymocytes from
the dn Jnk1 mice are also resistant to anti-CD3–induced
apoptosis, similar to JNK1 mutant mice. These data strongly
argue for an essential role for JNK1 in positively regulating
mature T cell proliferation.
The observed proliferation defect correlates with and is
probably caused by decreased IL-2 production, as it is com-
pletely suppressed by exogenous IL-2. In addition to JNK1
and JNK2, the JNK activating kinase JNKK1/SEK1 was
also implicated in regulating T cell function (30). Chimeras
generated using Sek12/2 ES cells gave different results (30,
42). Nishina et al. (30) found defective T cell activation,
whereas Swat et al. (42) found normal activation of T cells
lacking SEK1. In the latter, SEK1-deficient lymphocytes
were found to be capable of JNK activation. Thus, it ap-
pears that the magnitude of the stimuli and the level of
JNK activation are important factors determining the effi-327 Sabapathy et al.
ciency of T cell activation. Taken together, our results in-
dicate that JNK1 has a positive rather than a negative effect
on NF-AT and T cell activation and that JNK1 and JNK2
have similar and overlapping roles in T cell function. Al-
though c-Jun is a relevant target of both JNKs in thy-
mocytes, it does not seem to be an important target in pe-
ripheral T cells, where both JNK isozymes contribute to
the induction of NF-AT rather than AP-1 activity.
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